Patel Akshilkumar, LaBarge Brandon, King Tonya S, Pradhan Sandeep, Warrick Joshua, Goyal Neerav
The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Department of Otolaryngology-Head and Neck Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.
SAGE Open Med. 2023 Sep 25;11:20503121231200103. doi: 10.1177/20503121231200103. eCollection 2023.
Mammary analog secretory carcinoma (MASC) is a classification of salivary gland tumors, recently included within the term secretory carcinoma. Previous descriptions of this diagnosis have largely consisted of case reports and case series with few studies investigating its clinical characteristics as compared to non-MASC tumors. Our objective was to use a large patient database to compare the clinical characteristics of mammary analog secretory carcinoma vs. non-mammary analog secretory carcinoma salivary gland tumors.
The National Cancer Database was queried between September and October 2022 for histological diagnosis of mammary analog secretory carcinoma and non-MASC salivary tumors. Patients diagnosed with mammary analog secretory carcinoma and non-mammary analog secretory carcinoma salivary tumors between the period of 2004 through 2019 were included in this analysis. Various demographic and clinical variables were abstracted from the database and compared using Wilcoxon rank sum and chi-square tests. Survival was compared between cohorts using Cox proportional hazards regression.
Overall, compared to non-mammary analog secretory carcinoma diagnoses ( = 47668), mammary analog secretory carcinoma tumors ( = 384) affected younger individuals, displayed favorable pathologic staging and tumor grade, and were less likely to invade surrounding tissues. Patients with mammary analog secretory carcinoma tumors also received treatment more quickly following diagnosis compared to patients with non-mammary analog secretory carcinoma tumors. The risk of death was 4.3 times greater for non-mammary analog secretory carcinoma diagnoses when adjusted for patient variables (hazard ratio = 4.3, 95% confidence interval [2.37-7.71], < 0.001).
Clinically, mammary analog secretory carcinoma salivary tumors have a more indolent course compared to other salivary cancers. Additional studies are needed to determine the natural history of this tumor type.
乳腺样分泌性癌(MASC)是唾液腺肿瘤的一种分类,最近被纳入分泌性癌这一术语范畴。此前关于该诊断的描述主要是病例报告和病例系列,与非MASC肿瘤相比,很少有研究调查其临床特征。我们的目的是使用一个大型患者数据库来比较乳腺样分泌性癌与非乳腺样分泌性癌唾液腺肿瘤的临床特征。
2022年9月至10月期间查询国家癌症数据库,以获取乳腺样分泌性癌和非MASC唾液腺肿瘤的组织学诊断信息。纳入2004年至2019年期间被诊断为乳腺样分泌性癌和非乳腺样分泌性癌唾液腺肿瘤的患者进行分析。从数据库中提取各种人口统计学和临床变量,并使用Wilcoxon秩和检验和卡方检验进行比较。使用Cox比例风险回归比较队列之间的生存率。
总体而言,与非乳腺样分泌性癌诊断(n = 47668)相比,乳腺样分泌性癌肿瘤(n = 384)影响的是更年轻的个体,显示出良好的病理分期和肿瘤分级,且侵犯周围组织的可能性较小。与非乳腺样分泌性癌肿瘤患者相比,乳腺样分泌性癌肿瘤患者在诊断后也更快接受治疗。在对患者变量进行调整后,非乳腺样分泌性癌诊断的死亡风险高4.3倍(风险比 = 4.3,95%置信区间[2.37 - 7.71],P < 0.001)。
临床上,乳腺样分泌性癌唾液腺肿瘤与其他唾液腺癌相比病程更为惰性。需要进一步研究来确定这种肿瘤类型的自然病程。